Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer
Up to 30 evaluable participants with known or suspected breast cancer (BIRADS 5 by imaging)
 will undergo FTT PET/CT imaging before primary surgery or neoadjuvant therapy. Patients
 undergoing neoadjuvant therapy may choose to have a second FTT PET/CT scan after the start of
 therapy (1 days to 3 weeks). FTT PET/CT uptake will be correlated with pathology measures and
 treatment response, in subjects undergoing neoadjuvant therapy
Inclusion Criteria:

 -  Participants will be ≥ 18 years of age

 -  Known or suspected (BIRADS 5 on imaging) primary breast cancer

 -  At least one breast lesion one breast lesion that is 1 cm or greater in size by
 standard imaging (e.g. mammography, ultrasound or breast MRI). Only one type of
 imaging is required to show a lesion of 1 cm or greater in order for the patient to be
 eligible to participate in this study. Patients that have a prior diagnosis of primary
 breast cancer in the opposite breast can be included.

 -  Willing to allow use orcollection of pathology tissue for the purposes of research
 from either clinical biopsy or surgical procedure (if adequate tissue is available) or
 research only biopsy

 -  Participants must be informed of the investigational nature of this study and be
 willing to provide written informed consent and participate in this study in
 accordance with institutional and federal guidelines prior to study-specific
 procedures.

 Exclusion Criteria:

 -  Females who are pregnant or breast feeding at the time of screening will not be
 eligible for this study; a urine pregnancy test will be performed in women of
 child-bearing potential at screening.

 -  Inability to tolerate imaging procedures in the opinion of an investigator or treating
 physician

 -  Any current medical condition, illness, or disorder as assessed by medical record
 review and/or self-reported that is considered by a physician investigator to be a
 condition that could compromise participant safety or successful participation in the
 study